Applied Therapeutics, Inc. (APLT) Analyse boursière

Présentation de l'entreprise

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing a pipeline of novel product candidates targeting validated molecular addresses within indications characterized by significant unmet medical needs in the United States. The enterprise functions within the healthcare sector and specifically the biotechnology industry, a classification that defines its focus on high-risk, high-reward research and development rather than established manufacturing or commercialization of generic goods. The company's financial scale is currently defined by a market capitalization of $14.86M and an annual revenue of $1.00M, supported by an organizational structure comprising 28 employees. These valuation and revenue metrics indicate a micro-cap profile typical of early-stage development firms, where the primary capital allocation is directed toward clinical trials and regulatory milestones rather than dividend generation or profit distribution.

Santé financière

The company reported revenue of $1.00M over the trailing twelve months, yet recorded a net income of $-18,138,000 and an EBITDA of $-99,611,000, a disparity that reveals a cost structure dominated by substantial research and development expenditures and operating overheads that far exceed current sales generation. The free cash flow stands at $-128,157,504, indicating a significant cash burn rate that necessitates external financing or the utilization of existing cash reserves to sustain ongoing operational activities and clinical progress. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of -1796.7%, and a profit margin of 0.0%, figures that collectively demonstrate the pre-commercial nature of the business where revenue does not yet cover the variable and fixed costs associated with bringing products to market. Regarding liquidity and leverage, the company holds $11.95M in cash against $2.50M in debt, while the debt-to-equity ratio is listed as N/A due to the negative equity position implied by the losses, suggesting a capital structure reliant on equity financing rather than traditional debt obligations. The current ratio is 0.96, a metric that indicates the company's current assets are slightly below its current liabilities, highlighting a tight short-term liquidity position that requires careful management of working capital. Furthermore, the return on equity is -680.5% and the return on assets is -88.3%, metrics that reveal the current inability to generate positive returns on shareholder capital or total assets, a common characteristic for clinical-stage biotechs still in the investment phase of their lifecycle.

Évaluation de la valorisation

The valuation metrics present a complex picture with a trailing P/E ratio of N/A and a forward P/E of -0.26, implying that the market does not currently price in positive earnings and that the forward metric is distorted by the negative earnings base typical of development companies. The price-to-book ratio is recorded at -25.75, a negative figure that indicates the market capitalization is below the book value of assets, reflecting the intangible nature of the company's value which resides primarily in its intellectual property and clinical pipeline rather than tangible assets. Alternative valuation measures such as the price-to-sales ratio of 14.86 and an EV/EBITDA of -0.05 suggest that investors are pricing the company based on its revenue potential and asset backing rather than profitability, which is standard for firms with no current earnings. The stock has demonstrated significant price volatility with a 52-week high of $1.50 and a 52-week low of $0.09, meaning the current trading environment fluctuates within a range where the price is currently situated relative to these historical extremes. The beta value of 2.08 indicates that the stock price is highly volatile and moves with approximately double the magnitude of the broader market, reflecting the heightened risk premium demanded by investors for biotechnology assets.

Growth & Income

Revenue growth over the past year has accelerated to 719.7%, while earnings growth is listed as N/A due to the negative net income position, implying that the expansion in revenue has not yet translated into profitability and that earnings are not growing faster than revenue because they are currently contracting relative to historical loss levels. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm reinvests all available resources and earnings into its growth initiatives rather than distributing cash to shareholders. This reinvestment strategy is essential for clinical-stage companies to fund their product candidates and reach critical development milestones before they can generate commercial revenue. Overall, the growth and income profile is characterized by aggressive revenue expansion coupled with substantial cash burn and an absence of dividend income, positioning the equity as a pure play on the success of future product approvals rather than a current income generator.